Breo Ellipta (Fluticasone/Vilanterol) Patent Expiration, LOE Window & CMS Spending

Breo Ellipta (Fluticasone/Vilanterol) by GSK: FDA Orange Book LOE 2031-04-11, 0 AB generics, $1.40B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN204275 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-04-11
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.40B
2024 Medicare Part D Spend$1.36B
2024 Medicaid Spend$42.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.